{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T18:34:05Z","timestamp":1784399645942,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tesaro","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00280-017-3455-x","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T01:27:37Z","timestamp":1508203657000},"page":"39-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-3384","authenticated-orcid":false,"given":"L.","family":"van Andel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kansra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sanghvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Tibben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gebretensae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"3455_CR1","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G et al (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14:882\u2013892. doi:\n                        10.1016\/S1470-2045(13)70240-7","journal-title":"Lancet Oncol"},{"key":"3455_CR2","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154\u20132164. doi:\n                        10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"key":"3455_CR3","unstructured":"US Food and Drug Administration (2003) Guidance for industry bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations. Rockville, MD. \n                        https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3995B1_07_GFI-BioAvail-BioEquiv.pdf\n                        \n                    . Accessed 12 Feb 2015"},{"key":"3455_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1023\/A:1007574217260","volume":"17","author":"LJ Lesko","year":"2000","unstructured":"Lesko LJ, Rowland M, Peck CC, Blaschke TF (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 17:1335\u20131344. doi:\n                        10.1023\/A:1007574217260","journal-title":"Pharm Res"},{"key":"3455_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1517\/17425255.2.3.419","volume":"2","author":"G Lappin","year":"2006","unstructured":"Lappin G, Rowland M, Garner RC (2006) The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol 2:419\u2013427. doi:\n                        10.1517\/17425255.2.3.419","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3455_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4155\/bio.10.6","volume":"2","author":"RC Garner","year":"2010","unstructured":"Garner RC (2010) Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2:429\u2013440. doi:\n                        10.4155\/bio.10.6","journal-title":"Bioanalysis"},{"key":"3455_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0009-9236(96)90208-8","volume":"60","author":"ET Hellriegel","year":"1996","unstructured":"Hellriegel ET, Bjornsson TD, Hauck WW (1996) Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 60:601\u2013607. doi:\n                        10.1016\/S0009-9236(96)90208-8","journal-title":"Clin Pharmacol Ther"},{"key":"3455_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/jcph.569","volume":"56","author":"G Lappin","year":"2016","unstructured":"Lappin G (2016) Approaches to intravenous clinical pharmacokinetics: recent developments with isotopic microtracers. J Clin Pharmacol 56:11\u201323. doi:\n                        10.1002\/jcph.569","journal-title":"J Clin Pharmacol"},{"key":"3455_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1517\/17425255.2013.786042","volume":"9","author":"G Lappin","year":"2013","unstructured":"Lappin G, Noveck R, Burt T (2013) Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol 9:817\u2013834. doi:\n                        10.1517\/17425255.2013.786042","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3455_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.4155\/bio.13.318","volume":"6","author":"XS Xu","year":"2014","unstructured":"Xu XS, Jiang H, Christopher LJ et al (2014) Sensitivity-based analytical approaches to support human absolute bioavailability studies. Bioanalysis 6:497\u2013504. doi:\n                        10.4155\/bio.13.318","journal-title":"Bioanalysis"},{"key":"3455_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/bcp.12468","volume":"78","author":"C Beaumont","year":"2014","unstructured":"Beaumont C, Young GC, Cavalier T, Young MA (2014) Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches. Br J Clin Pharmacol 78:1185\u20131200. doi:\n                        10.1111\/bcp.12468","journal-title":"Br J Clin Pharmacol"},{"key":"3455_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1365-2125.2012.04391.x","volume":"75","author":"DW Boulton","year":"2013","unstructured":"Boulton DW, Kasichayanula S, Keung CFA et al (2013) Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol 75:763\u2013768. doi:\n                        10.1111\/j.1365-2125.2012.04391.x","journal-title":"Br J Clin Pharmacol"},{"key":"3455_CR13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/jcph.127","volume":"53","author":"CL Denton","year":"2013","unstructured":"Denton CL, Minthorn E, Carson SW et al (2013) Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors. J Clin Pharmacol 53:955\u2013961. doi:\n                        10.1002\/jcph.127","journal-title":"J Clin Pharmacol"},{"key":"3455_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/bcp.12373","volume":"78","author":"C Leonowens","year":"2014","unstructured":"Leonowens C, Pendry C, Bauman J et al (2014) Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Br J Clin Pharmacol 78:524\u2013532. doi:\n                        10.1111\/bcp.12373","journal-title":"Br J Clin Pharmacol"},{"key":"3455_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jchromb.2016.11.020","volume":"1040","author":"L Andel van","year":"2017","unstructured":"van Andel L, Zhang Z-Y, Lu S et al (2017) Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. J Chromatogr B 1040:14\u201321. doi:\n                        10.1016\/j.jchromb.2016.11.020","journal-title":"J Chromatogr B"},{"key":"3455_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0451-2","author":"L Andel van","year":"2017","unstructured":"van Andel L, Zhang Z, Lu S et al (2017) Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs. doi:\n                        10.1007\/s10637-017-0451-2","journal-title":"Invest New Drugs"},{"key":"3455_CR17","volume-title":"Clinical pharmacokinetics: concepts and applications","author":"M Rowland","year":"1995","unstructured":"Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd\u00a0edn. Lippincott Williams & Wilkins, Philadelphia","edition":"3"}],"updated-by":[{"DOI":"10.1007\/s00280-017-3474-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000}}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3455-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T02:31:21Z","timestamp":1515033081000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3455-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3455"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3455-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00280-017-3474-7","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]}}}